A Phase II, Open-label, Multicentre, Pharmacokinetic, Pharmacodynamics and Safety Study of a New Paediatric Eurartesim Dispersible Formulation and Crushed Film Coated Eurartesim Tablet, in Infant Patients With P. Falciparum Malaria

Trial Profile

A Phase II, Open-label, Multicentre, Pharmacokinetic, Pharmacodynamics and Safety Study of a New Paediatric Eurartesim Dispersible Formulation and Crushed Film Coated Eurartesim Tablet, in Infant Patients With P. Falciparum Malaria

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Oct 2017

At a glance

  • Drugs Dihydroartemisinin/piperaquine (Primary)
  • Indications Falciparum malaria
  • Focus Pharmacokinetics
  • Sponsors sigma-tau SpA
  • Most Recent Events

    • 23 Oct 2017 Primary endpoint (PCR-corrected Adequate Clinical and Parasitological Response (ACPR), dispersible tablet formulation of DHA/PQP Vs crushed tablet) has been met as per the results published in the Antimicrobial Agents and Chemotherapy
    • 23 Oct 2017 Results published in the Antimicrobial Agents and Chemotherapy
    • 08 Jul 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top